Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2020
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyMerry Jennifer Markham, Kerri Wachter, Neeraj Agarwal, et al.
The New England Journal of Medicine|October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung CancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with CrizotinibEzra Y Rosen, Melissa L Johnson, Sarah E Clifford, et al.
Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Discovery|February 13, 2025
Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule ReactivatorAnna M Puzio-Kuter, Lizhong Xu, Mary Kate McBrayer, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.
Nature Medicine|March 28, 2024
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim resultsAmy R Rappaport, Chrisann Kyi, Monica Lane, et al.
Pageof 10